Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders (Video Program)Incidence of venetoclax-associated tumor lysis syndrome in MM
1:29 minutes.
TRANSCRIPTION:
DR LOVE: Of course, there’s a lot of thinking now about the potential of tumor lysis syndrome in CLL with venetoclax. DR FONSECA: Yes. DR LOVE: There are all these algorithms set up to try to prevent it. The minimal data I’ve seen that’s out there, I don’t see that in the myeloma studies. Has it been reported? DR FONSECA: It hasn’t been reported, but we’re getting questions from our colleagues who say, “Well, if you’re going to start using venetoclax” — I think in CLL, they used to admit the patients to the hospital because — DR LOVE: But it kind of depends on their risk. DR FONSECA: At the beginning and where they were with their tumor burden. So something we’ll have to pay attention to. But I think there’s very nice crosstalk there, where we might do it maybe with bortezomib, maybe with a CyBorD approach with venetoclax. The same would be true probably for other lymphomas. And I don’t follow this as closely, but I could only imagine mantle cell, bortezomib. You have venetoclax. You have the 11;14. So there might be some crosstalk between the different late B-cell tumor types. DR LOVE: I mean, for example, in your man with plasma cell leukemia, are you going to be thinking about tumor lysis syndrome? DR RAJE: In his case, for sure, because he has a very high tumor burden. And that’s something we would, routinely, with whatever treatment we use. So the difference between some of the CLLs and myeloma is myeloma cells don’t proliferate as fast as the CLL cells. We do see tumor lysis, but it’s rare. And that’s why I think it’s not as reported as with CLL. It’s just to do with the labeling index of those cells. |